Pliant Therapeutics, Inc. (PLRX)

Several events have impacted Pliant Therapeutics' stock price in the past six months. In December 2025, the company announced interim data from PLN-101095 and participated in the Piper Sandler Healthcare Conference. January 2026 saw insider selling activity. February 2026 involved participation in the Oppenheimer Healthcare Life Science Conference. In March 2026, Pliant provided a corporate update and reported Q4 2025 financial results, announced an upcoming presentation of Phase 1 data for PLN-101095, had its price target lowered by Canaccord, terminated a prior sales agreement and entered a new one with Leerink Partners LLC, and experienced stock price fluctuations with a decline of 13.33% from March 31, 2025.

As a clinical-stage biopharmaceutical company, Pliant Therapeutics, Inc. does not have commercialized products or services that are subject to traditional demand seasonality. Its revenue and operational focus are primarily on research and development, clinical trials, and pipeline progression, rather than sales of products to consumers or businesses. Therefore, demand seasonality for its therapeutic candidates is not applicable.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases and solid tumors, utilizing a precision medicine approach targeting integrin-mediated signaling pathways. Its major product candidates include Bexotegrast (PLN-74809), an integrin inhibitor whose development for IPF was discontinued in August 2025; PLN-101095, an integrin inhibitor in Phase 1 trials for solid tumors; PLN-1474, an integrin inhibitor for NASH with liver fibrosis; and PLN-101325, an integrin agonist in a Phase 1 study for muscular dystrophies. The company also maintains a drug discovery platform with a library of integrin binding molecules.

Pliant Therapeutics, Inc. is headquartered in South San Francisco, California, United States. Information regarding a broader geographic operational or market footprint for the company's activities beyond its headquarters is not explicitly detailed in the provided search results.

Pliant Therapeutics' brand reputation is tied to its clinical trial progress and corporate developments. The discontinuation of bexotegrast in IPF negatively impacted its reputation, while positive early data for PLN-101095 bolstered confidence. A workforce reduction and cost-saving initiatives can be viewed as a strategic move but may also raise concerns.

Pliant Therapeutics, Inc. has a mixed ownership structure, with significant institutional and individual investors. Institutional investors hold approximately 39.06% to 75.41% of the company's stock, with major shareholders including Tang Capital Management Llc and Vanguard Group Inc. Matthew G. Robinson is the largest individual shareholder, owning 25.95% of the company. Insiders collectively hold approximately 2.48% to 42.31% of the stock, while retail investors hold approximately 0.00% to 48.20%.